Aethlon Medical (AEMD) investor relations material

Investment highlights and platform overview

• Hemopurifier platform demonstrates clearance of enveloped viruses and extracellular vesicles in vitro and in patients, with two FDA Breakthrough Device designations for cancer and life-threatening viruses.

• Multi-indication potential spans oncology, infectious disease, and transplant, supported by a strong patent portfolio extending to 2044 and capital-efficient development aided by Australia's R&D rebate.

• Proprietary technology has shown a favorable safety profile in 173 treatments across 44 patients, with demonstrated removal of life-threatening viruses and tumor-derived EVs.

Mechanism of action and clinical data

• Hemopurifier uses a dialysis-like cartridge with a proprietary GNA lectin affinity resin to capture extracellular vesicles and enveloped viruses from blood, without plasmapheresis.

• In vitro and in vivo studies show removal of 92-99% of cancer-derived EVs and significant reduction of exosomes in patients with cancer and severe viral infections.

• Ongoing Australian oncology trial shows no dose-limiting toxicities, with central lab results pending on EV removal and anti-tumor CD8 T cell changes.

Oncology and market opportunity

• Tumor-derived EVs facilitate metastasis, immune evasion, and therapy resistance; Hemopurifier targets these, potentially improving outcomes for the 60-70% of patients not responding to checkpoint inhibitors.

• Checkpoint inhibitor market projected to grow from $74B in 2026 to $142B by 2031, with Hemopurifier offering a novel mechanism to address non-responders.